Roche’s Elecsys IL-6 Test Receives the US FDA’s EUA to Identify Patients at High Risk of Severe Inflammatory Response with COVID-19

Roche’s Elecsys IL-6 Test Receives the US FDA’s EUA to Identify Patients at High Risk of Severe Inflammatory Response with COVID-19

Shots:

  • The US FDA has issued a EUA for the Elecsys IL-6 test which measures levels of the biomarker IL-6 and can be used to identify patients with confirmed COVID-19 disease with a high risk of intubation with mechanical ventilation
  • The test allows the physician to decide early if a patient with confirmed COVID-19 illness requires mechanical ventilation
  • The test will be available in the countries accepting CE mark and will run on Roche’s Cobas e analyzers, widely available across the globe. These fully automated systems can provide test results in ~18 minutes, with a test throughput of up to 300 tests/hour, depending on the analyzer

Click here ­to­ read full press release/ article | Ref: Roche | Image: Roche